121 related articles for article (PubMed ID: 15258697)
1. Chemosensitivity and radiosensitivity profiles of four new human epithelial ovarian cancer cell lines exhibiting genetic alterations in BRCA2, TGFbeta-RII, KRAS2, TP53 and/or CDNK2A.
Samouëlian V; Maugard CM; Jolicoeur M; Bertrand R; Arcand SL; Tonin PN; Provencher DM; Mes-Masson AM
Cancer Chemother Pharmacol; 2004 Dec; 54(6):497-504. PubMed ID: 15258697
[TBL] [Abstract][Full Text] [Related]
2. Expression profiles of 290 ESTs mapped to chromosome 3 in human epithelial ovarian cancer cell lines using DNA expression oligonucleotide microarrays.
Manderson EN; Mes-Masson AM; Novak J; Lee PD; Provencher D; Hudson TJ; Tonin PN
Genome Res; 2002 Jan; 12(1):112-21. PubMed ID: 11779836
[TBL] [Abstract][Full Text] [Related]
3. Microarray analysis of gene expression mirrors the biology of an ovarian cancer model.
Tonin PN; Hudson TJ; Rodier F; Bossolasco M; Lee PD; Novak J; Manderson EN; Provencher D; Mes-Masson AM
Oncogene; 2001 Oct; 20(45):6617-26. PubMed ID: 11641787
[TBL] [Abstract][Full Text] [Related]
4. Patterns of expression of chromosome 17 genes in primary cultures of normal ovarian surface epithelia and epithelial ovarian cancer cell lines.
Presneau N; Mes-Masson AM; Ge B; Provencher D; Hudson TJ; Tonin PN
Oncogene; 2003 Mar; 22(10):1568-79. PubMed ID: 12629520
[TBL] [Abstract][Full Text] [Related]
5. Transcriptome analysis of serous ovarian cancers identifies differentially expressed chromosome 3 genes.
Birch AH; Quinn MC; Filali-Mouhim A; Provencher DM; Mes-Masson AM; Tonin PN
Mol Carcinog; 2008 Jan; 47(1):56-65. PubMed ID: 17620309
[TBL] [Abstract][Full Text] [Related]
6. Mutation analysis of BRCA1, TP53, and KRAS2 in ovarian and related pelvic tumors.
Tworek H; Peng R; Fetzer S; Werness BA; Piver MS; Allen HJ; DiCioccio RA
Cancer Genet Cytogenet; 1999 Jul; 112(2):105-18. PubMed ID: 10686936
[TBL] [Abstract][Full Text] [Related]
7. Valproic Acid as a Promising Co-Treatment With Paclitaxel and Doxorubicin in Different Ovarian Carcinoma Cell Lines.
Kwiecińska P; Taubøll E; Grzyb E; Fiedor E; Ptak A; Gregoraszczuk EL
Int J Gynecol Cancer; 2016 Nov; 26(9):1546-1556. PubMed ID: 27654264
[TBL] [Abstract][Full Text] [Related]
8. A useful cell system for studying the regulation of 17HSD/KSR type 2 activity and expression in ovarian epithelial cancer.
Provost PR; Lima PH; Tremblay Y; Blomquist CH
J Steroid Biochem Mol Biol; 2010 Oct; 122(4):295-301. PubMed ID: 20600897
[TBL] [Abstract][Full Text] [Related]
9. Down-regulation of BRCA1 and BRCA2 in human ovarian cancer cells exposed to adriamycin and ultraviolet radiation.
Fan S; Twu NF; Wang JA; Yuan RQ; Andres J; Goldberg ID; Rosen EM
Int J Cancer; 1998 Aug; 77(4):600-9. PubMed ID: 9679765
[TBL] [Abstract][Full Text] [Related]
10. Altered expression of TGFB receptors and mitogenic effects of TGFB in pancreatic carcinomas.
Jonson T; Albrechtsson E; Axelson J; Heidenblad M; Gorunova L; Johansson B; Höglund M
Int J Oncol; 2001 Jul; 19(1):71-81. PubMed ID: 11408925
[TBL] [Abstract][Full Text] [Related]
11. Regulation of BRCA1 and BRCA2 expression in human breast cancer cells by DNA-damaging agents.
Andres JL; Fan S; Turkel GJ; Wang JA; Twu NF; Yuan RQ; Lamszus K; Goldberg ID; Rosen EM
Oncogene; 1998 Apr; 16(17):2229-41. PubMed ID: 9619832
[TBL] [Abstract][Full Text] [Related]
12. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.
Walsh T; Casadei S; Coats KH; Swisher E; Stray SM; Higgins J; Roach KC; Mandell J; Lee MK; Ciernikova S; Foretova L; Soucek P; King MC
JAMA; 2006 Mar; 295(12):1379-88. PubMed ID: 16551709
[TBL] [Abstract][Full Text] [Related]
13. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.
Perego P; Giarola M; Righetti SC; Supino R; Caserini C; Delia D; Pierotti MA; Miyashita T; Reed JC; Zunino F
Cancer Res; 1996 Feb; 56(3):556-62. PubMed ID: 8564971
[TBL] [Abstract][Full Text] [Related]
14. TP53 and KRAS2 mutations in plasma DNA of healthy subjects and subsequent cancer occurrence: a prospective study.
Gormally E; Vineis P; Matullo G; Veglia F; Caboux E; Le Roux E; Peluso M; Garte S; Guarrera S; Munnia A; Airoldi L; Autrup H; Malaveille C; Dunning A; Overvad K; Tjønneland A; Lund E; Clavel-Chapelon F; Boeing H; Trichopoulou A; Palli D; Krogh V; Tumino R; Panico S; Bueno-de-Mesquita HB; Peeters PH; Pera G; Martinez C; Dorronsoro M; Barricarte A; Navarro C; Quirós JR; Hallmans G; Day NE; Key TJ; Saracci R; Kaaks R; Riboli E; Hainaut P
Cancer Res; 2006 Jul; 66(13):6871-6. PubMed ID: 16818665
[TBL] [Abstract][Full Text] [Related]
15. Anomalies of the TGF-beta postreceptor signaling pathway in ovarian cancer cell lines.
Hu W; Wu W; Nash MA; Freedman RS; Kavanagh JJ; Verschraegen CF
Anticancer Res; 2000; 20(2A):729-33. PubMed ID: 10810347
[TBL] [Abstract][Full Text] [Related]
16. Sensitivity to paclitaxel is not related to p53-dependent apoptosis in ovarian cancer cells.
Takahashi M; Kigawa J; Minagawa Y; Itamochi H; Shimada M; Kamazawa S; Sato S; Akeshima R; Terakawa N
Eur J Cancer; 2000 Sep; 36(14):1863-8. PubMed ID: 10974635
[TBL] [Abstract][Full Text] [Related]
17. No association between radiosensitivity and TP53 status, G1 arrest or protein levels of p53, myc, ras or raf in human melanoma lines.
Danielsen T; Smith-Sørensen B; Grønlund HA; Hvidsten M; Børresen-Dale AL; Rofstad EK
Int J Radiat Biol; 1999 Sep; 75(9):1149-60. PubMed ID: 10528923
[TBL] [Abstract][Full Text] [Related]
18. Re-assigning the histologic identities of COV434 and TOV-112D ovarian cancer cell lines.
Karnezis AN; Chen SY; Chow C; Yang W; Hendricks WPD; Ramos P; Briones N; Mes-Masson AM; Bosse T; Gilks CB; Trent JM; Weissman B; Huntsman DG; Wang Y
Gynecol Oncol; 2021 Feb; 160(2):568-578. PubMed ID: 33328126
[TBL] [Abstract][Full Text] [Related]
19. p53 status does not affect sensitivity of human ovarian cancer cell lines to paclitaxel.
Debernardis D; Siré EG; De Feudis P; Vikhanskaya F; Valenti M; Russo P; Parodi S; D'Incalci M; Broggini M
Cancer Res; 1997 Mar; 57(5):870-4. PubMed ID: 9041188
[TBL] [Abstract][Full Text] [Related]
20. Molecular characterization of 7 new established cell lines from high grade serous ovarian cancer.
Kreuzinger C; Gamperl M; Wolf A; Heinze G; Geroldinger A; Lambrechts D; Boeckx B; Smeets D; Horvat R; Aust S; Hamilton G; Zeillinger R; Cacsire Castillo-Tong D
Cancer Lett; 2015 Jul; 362(2):218-28. PubMed ID: 25862976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
